News ArchivesRead News
Beauty treatment gives relief to Parkinson’s patients
Thursday April 29, 2010
Health News - One of the world’s most fashionable beauty treatments is gaining popularity for something other than the war on wrinkles.
Botulinum Toxin, commonly known as Botox, is being used at the Muhammad Ali Parkinson Centre (MAPC) at Barrow Neurological Institute to help manage symptoms associated with Parkinson’s disease and other movement disorders.
“Botox is the most powerful nerve toxin known to man and it’s dramatically improving the quality of life for people with Parkinson’s,” says Guillermo Moguel-Cobos, movement disorder neurologist at the Centre. “For this type of treatment, it’s a miracle drug.”
Parkinson’s disease is characterised by muscle rigidity, tremors, a slowing of physical movement and a loss of physical movement.
Botox, which has been purified and then diluted, can be injectedstraight into the muscle, relieving the spasms and most importantly, the pain.
“It’s a medical treatment but it’s also an art to administer. Every patient receives Botox differently in different muscles, in different locations and in different dosages, so experience with the drug and the disease is crucial,” says Moguel-Cobos.
MAPC has been using Botox to treat Parkinson’s and other movement disorders such as dystonia since the early 1990s.
The treatment has recently gained popularity due to the growing number of patients at the MAPC. Out of approximately 1,600 patient visits each year, 30 percent receive Botox injections.
To help with the demand, the Centre runs a Botox Clinic two days a week. Depending on the patient and the severity of their movement disorder, their Botox can take 30 minutes to an hour to inject and can take up to seven days to become effective.
For most, the drug will provide significant but variable relief of symptoms that can last up to three months, says a release from the Barrow Neurological Institute.
Recent NewsOct 18 - Fighting Parkinson's disease through dance
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show